West Pharmaceutical Services (West Pharmaceutical Services) Cash And Cash Equivalents

: $854 Mil (As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

West Pharmaceutical Services's quarterly cash and cash equivalents increased from Jun. 2023 ($796.30 Mil) to Sep. 2023 ($898.60 Mil) but then stayed the same from Sep. 2023 ($898.60 Mil) to Dec. 2023 ($853.90 Mil).

West Pharmaceutical Services's annual cash and cash equivalents increased from Dec. 2021 ($762.60 Mil) to Dec. 2022 ($894.30 Mil) but then declined from Dec. 2022 ($894.30 Mil) to Dec. 2023 ($853.90 Mil).

West Pharmaceutical Services Cash And Cash Equivalents Historical Data

The historical data trend for West Pharmaceutical Services's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

439.10

615.50

762.60

894.30

853.90

West Pharmaceutical Services Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																894.30	886.30	796.30	898.60	853.90

West Pharmaceutical Services Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

West Pharmaceutical Services (NYSE:WST) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

West Pharmaceutical Services Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services (West Pharmaceutical Services) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

WPS:Germany

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-0645

Website

https://www.westpharma.com

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.

Executives

Chad Winters	officer: VP, CAO & Controller	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Charles Witherspoon	officer: VP & Treasurer	530 HERMAN O WEST DRIVE, EXTON PA 19341
Annette F Favorite	officer: Sr. VP Human Resources Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark	officer: Senior Vice President	530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai	officer: VP Corp Development & Strategy	530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Silji Abraham	officer: Chief Digital & Trans Officer	5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Eric Mark Green	officer: Chief Executive Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Bernard Birkett	officer: Sr VP, CFO & Treasurer	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Thomas W Hofmann	director	FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph	director	9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay	officer: SVP, GC & Corporate Secretary	530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller	officer: Sr. VP, GC & Corp. Sec.	530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo	officer: SVP, Glob Ops and Supply Chain	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel	director	940 WINTER STREET, WALTHAM MA 02451